文献速递妇科

妊娠滋养细胞肿瘤的化疗耐药与风险分层:系统综述与网状Meta分析

Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta‐analysis
RSS 订阅 · Acta Obstetricia et Gynecologica Scandinavica · 2026-10-26

该系统综述与网状Meta分析纳入53项研究、7585例妊娠滋养细胞肿瘤患者,汇总化疗耐药率为23.8%(95%CI 20.7%–27.1%,p<0.001)。治疗前β-hCG较高(尤其>105 IU/L)、肿瘤负荷较大、FIGO分期/评分较高及绒毛膜癌与更高的耐药风险相关;探索性网状分析中,含依托泊苷方案显示较低的预测耐药风险。

要点

  • 妊娠滋养细胞肿瘤汇总化疗耐药率为23.8%(95%CI 20.7%–27.1%)。
  • 治疗前β-hCG>105 IU/L、FIGO评分高、肿瘤直径≥5 cm、转移及≥5个转移灶与更高耐药风险相关。
  • 探索性排序分析中甲氨蝶呤与氟尿嘧啶预测耐药排名较高,依托泊苷及FAEV方案排名较低。

核心结论

  • 约四分之一的妊娠滋养细胞肿瘤患者发生化疗耐药。
  • 治疗前因素(包括可获得时的临床病理类型、肿瘤负荷、FIGO分期/评分及治疗前β-hCG水平)与化疗耐药风险相关。
  • 探索性网状分析中,含依托泊苷方案显示较低的预测化疗耐药。

研究设计与样本

  • 系统综述与配对及网状Meta分析,检索PubMed、Embase、Cochrane Library、Web of Science、CBM、CNKI、VIP和Wanfang共8个数据库,检索时间自建库至2025年8月26日。
  • 两名评价者独立筛选文献、提取数据并使用RTI Item Bank评估偏倚风险。
  • 共纳入53项研究、7585例患者,其中1997例耐药病例。
  • 配对Meta分析汇总化疗耐药率并评估治疗前因素与耐药的关联;采用频率学随机效应网状Meta分析比较各化疗方案的耐药风险,以累积排名曲线下面积(SUCRA)汇总排序概率。

主要发现

  • 汇总化疗耐药率为23.8%(95%CI 20.7%–27.1%,p<0.001)。
  • 与更高化疗耐药相关的因素包括:绒毛膜癌、前次足月妊娠、高FIGO评分、治疗前β-hCG较高(尤其>105 IU/L)、距前次妊娠间隔较长(7–12个月和>12个月)、肿瘤负荷较大(肿瘤直径≥5 cm、存在转移、≥5个转移灶)、FIGO II期或IV期疾病,以及一线单药化疗。
  • 探索性排序分析中,甲氨蝶呤(MTX)与氟尿嘧啶(FU)的预测耐药排名倾向于较高,依托泊苷(ETP)与FAEV方案(氟尿嘧啶+放线菌素D+依托泊苷+长春新碱)的预测耐药排名倾向于较低。

关键数值与推荐

  • 汇总化疗耐药率为23.8%(95%CI 20.7%–27.1%,p<0.001),基于53项研究、7585例患者、1997例耐药病例。
  • 治疗前β-hCG>105 IU/L与更高的化疗耐药相关。
  • 肿瘤直径≥5 cm、存在转移、≥5个转移灶与更高的化疗耐药相关。
  • 距前次妊娠间隔7–12个月和>12个月与更高的化疗耐药相关。
  • FIGO II期或IV期疾病及一线单药化疗与更高的化疗耐药相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Higher pretreatment β-hCG, greater tumor burden, higher FIGO stage/score, and choriocarcinoma were associated with higher chemoresistance risk in gestational trophoblastic neoplasia. In exploratory network analyses, etoposide-containing regimens showed lower predicted chemoresistance. Abstract Introduction Gestational trophoblastic neoplasia (GTN) is highly chemosensitive, but resistance to initial chemotherapy remains clinically important despite International Federation of Gynecology and Obstetrics (FIGO) score-guided management. Evidence on pretreatment predictors of chemoresistance and comparative chemoresistance across chemotherapy regimens remains limited. This study aimed to estimate the burden of chemoresistance, identify pretreatment risk factors, and compare chemotherapy regimens using pairwise and network meta-analysis to inform risk stratification and future treatment optimization. Material and Methods Eight databases (PubMed, Embase, Cochrane Library, Web of Science, CBM, CNKI, VIP, and Wanfang) were searched from inception to August 26, 2025. Two reviewers independently screened records, extracted data, and assessed risk of bias using the RTI Item Bank. Pairwise meta-analyses were used to pool the chemoresistance rate and evaluate associations between pretreatment factors and chemoresistance. A frequentist random-effects network meta-analysis was performed to compare chemoresistance risks across chemotherapy regimens, with ranking probabilities summarized using the surface under the cumulative ranking curve (SUCRA). Results Fifty-three studies involving 7585 patients and 1997 resistant cases yielded a pooled chemoresistance rate of 23.8% (95% CI: 20.7%–27.1%; p < 0.001). Higher chemoresistance was associated with choriocarcinoma, antecedent full-term pregnancy, a high FIGO score, higher pretreatment β-hCG, especially > 105 IU/L, longer intervals from antecedent pregnancy (7–12 and > 12 months), greater tumor burden (tumor diameter ≥5 cm, presence of metastasis, and ≥ 5 metastatic lesions), FIGO stage II or IV disease, and first-line single-agent chemotherapy. In exploratory ranking analyses, methotrexate (MTX) and fluorouracil (FU) tended to rank higher for predicted chemoresistance, whereas etoposide (ETP) and FU + actinomycin D + etoposide + vincristine (FAEV) tended to rank lower. Conclusions Approximately one quarter of patients with GTN develop chemoresistance. Pretreatment factors, including clinicopathologic type when available, tumor

来源:Acta Obstetricia et Gynecologica Scandinavica,查看原文。版权归原作者所有。

引用

  1. Acta Obstetricia et Gynecologica Scandinavica:Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta‐analysis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。